Document is current
Any future updates will be listed below
-
Authors
Distler, Jörg H. W. https://orcid.org/0000-0001-7408-9333
Launay, David https://orcid.org/0000-0003-1840-1817
Feghali-Bostwick, Carol https://orcid.org/0000-0002-6750-6407
Matei, Alexandru-Emil https://orcid.org/0000-0003-1248-3145
Trojanowska, Maria https://orcid.org/0000-0001-9550-7178
Gudjonsson, Johann E. https://orcid.org/0000-0002-0080-0812
- License Information
-
More Information
Article History
Accepted: 17 December 2025
First Online: 26 January 2026
Competing interests
: J.H.W.D. has consulted for Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Callidatas, Calluna, Galapagos, GSK, Janssen, Kyverna, Novartis, Pfizer, Quell Therapeutics and UCB; has received research funding from Anamar, ARXX, BMS, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, Exo Therapeutics, Galapagos, GSK, Incyte, Inventiva, Kiniksa, Kyverna, Lassen Therapeutics, Mestag, Sanofi-Aventis, SpicaTx, RedX, UCB and ZenasBio; is the CEO of 4D Science and scientific lead of FibroCure. D.L. has consulted for AstraZeneca, Boehringer Ingelheim, CSL Behring, Biocryst, Takeda; has received research funding from Boehringer Ingelheim, Roche, CSL Behring, Biocryst and Servier. J.E.G. has consulted for Eli Lilly, Janssen, Johnson & Johnson, Incyte, BMS, Sanofi, Prometheus, Almirall, Kyowa-Kirin, Novartis, AnaptysBio, Boehringer Ingelheim, GSK, AbbVie and Galderma; has research funding from Almirall, AbbVie, Boehringer Ingelheim, GSK, Galderma, Novartis, Johnson & Johnson and Eli Lilly.
